A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
• Inadequate response to, loss of response to, or intolerance to available RA therapies.
• Stable doses of RA medications prior to screening
• Use of highly effective methods of contraception
Locations
Other Locations
Georgia
Xencor Investigative Site
RECRUITING
Tbilisi
New Zealand
Xencor Investigative Site
RECRUITING
Auckland
Republic of Moldova
Xencor Investigative Site
RECRUITING
Chisinau
Contact Information
Primary
Noriko Iikuni, MD, PhD
676-Aiinfo@xencor.com
Backup
Jaime Mertz
676-Aiinfo@xencor.com
Time Frame
Start Date: 2025-10-21
Estimated Completion Date: 2028-06
Participants
Target number of participants: 68
Treatments
Experimental: Dose Escalation
Plamotamab administered SC
Related Therapeutic Areas
Sponsors
Leads: Xencor, Inc.